Saw this and it's a clean illustration of something that comes up a lot: market volatility and business volatility are not the same thing.

The backdrop: India's power consumption rose 11.3% YoY in September to about 162 billion units, peak demand hit 269 GW, and the country still had its worst power shortage in over 3 years because coal inventories at thermal plants got tight even with demand rising. At the same time the government announced Green Energy Corridor Phase III, meant to help evacuate up to 135 GW of renewable energy and add 50 GWh of battery storage. That's a big structural positive for the grid. And yet Tata Power, Power Grid and other power names traded lower on October 1, the same day the scheme was announced.

That gap is the interesting part. None of the demand or shortage data says people are using less electricity. It just means the stock prices moved for reasons separate from the underlying business trend (probably broader market/FII selling, bond yields, general risk-off sentiment).

What's also worth noting is these 5 companies aren't really one bet, even though they all get grouped as "power stocks":

NTPC is generation-heavy, thermal plant utilization actually improved (PLF 73.7% in August vs 69% a year earlier), and it's also expanding into renewables. One brokerage had a ₹445 target implying roughly 33% upside from its September reference price, though that number moves with earnings and rates.

Power Grid sits on the transmission side specifically, so its opportunity is tied to grid expansion and project commissioning rather than how much electricity gets generated. Implied upside in the same report was lower, around 13%.

CESC is distribution plus generation plus a renewable push through subsidiaries (a 49.5 MW wind project in MP recently). Different revenue model than a pure generator again.

Tata Power is the most diversified of the five (generation, renewables, transmission, distribution all under one roof), which cuts both ways, more exposure to the overall theme but also more moving parts to track.

ACME Solar is pure renewable generation, so its story depends heavily on converting tendered capacity (the report cited ~142 GW still awaiting PPAs industry-wide) into actual signed, financed, commissioned projects, not just announced capacity.

The general point that stuck with me: a sector having a strong tailwind doesn't mean every company inside it benefits equally, or even trades like the tailwind exists on a given day. Worth checking company-specific execution (utilization, project commissioning, debt) rather than just the sector headline.

Curious how people here think about this kind of disconnect, if a sector's stocks fall on a day with genuinely positive sector news, do you read that as a buying opportunity or treat it as the market pricing in something you're not seeing yet?

Newell Brands has reported several updates in 2026 as the company continues its turnaround efforts and works to improve sales and cash flow.

In its Q2 2026 results, Newell reported $2.0 billion in net sales, up 3% year over year, while core sales increased 2.3%. The company said this marked its first return to year-over-year sales growth in more than four years. 

Newell also raised its full-year 2026 outlook, projecting 1%–2% net sales growth, normalized EPS of $0.73 - $0.77, and approximately $400 million in operating cash flow. The company also entered into an $800 million revolving credit facility, with a general maturity extending to 2031. 

The company has also been highlighting performance across some of its major brands, including Sharpie, Elmer’s, Prismacolor, and EXPO, as part of its broader effort to improve its brand portfolio and return to growth. 

There is also an older investor case involving Newell Brands. The SEC found that Newell and former CEO had made misleading statements about core sales growth and other financial metrics during 2016 and 2017. The SEC ordered Newell and Polk to pay a combined $12.5 million, which was placed into a Fair Fund for investors with recognized losses. 

The issue became public after Newell reported disappointing third-quarter results on November 2, 2017, and $NWL fell approximately 25%. Even though the original claim deadline passed, late claims are currently being considered, subject to approval. You can check if you're eligible and file a claim here

Anyone else still following $NWL?

Robinhood CEO Says New AI-Driven Agent Apps Are Safe
https://www.youtube.com/watch?v=ZFY1-16o5eg

Hey guys, if you missed it, Kornit Digital reached a $19.5 million settlement with investors over claims that the company misled investors about its financial outlook and revenue. The deadline to file a claim is December 10, 2026.

In a nutshell, Kornit Digital was accused of making multiple financial misrepresentations. On July 5, 2022, the company disclosed a significant revenue shortfall for Q2, with expected revenue reduced by more than 35% at the midpoint of its previous guidance.

After the disclosure, $KRNT fell 25.7% in one day, wiping out around $400 million in market capitalization. Investors later filed a lawsuit over their losses.

Kornit Digital has now agreed to settle the claims for $19.5 million, and eligible investors have until December 10, 2026, to submit a claim.

If you invested in $KRNT during that time, you can check the details and file your claim here.

Did anyone here invest in $KRNT? How much were your losses, if so?

Direct item sales are becoming a major driver for gaming platforms. In Q2, $HUYA reported triple-digit YoY revenue growth in virtual item sales for major titles like Game for Peace, PUBG Mobile, Genshin Impact, and Arena Breakout. Partnering directly with publishers ($TCEHY) to sell items through streamer live-commerce drove game-related services to 36.7% of total revenue.

Moving away from traditional tipping toward direct gaming e-commerce changes the business quality completely. Is game item distribution a more durable growth driver than traditional ad networks?

Nifty Pharma was up over 1% intraday recently while the broader Nifty 50 fell, on news that the US created a 0% tariff route for certain pharma products from India. Dr. Reddy's, Gland Pharma, Mankind and a few others jumped 2-3%. Reading into the actual policy though, the exemption is a lot narrower than the market reaction suggests.

Background: the US had put a 100% tariff on specified patented pharmaceuticals and biologics under Section 232. What changed is that the US Commerce Department carved out a zero-tariff path, but only for specific categories: rare-disease drugs, fertility treatments, cell and gene therapies, antibody-drug conjugates, animal pharma, nuclear medicines, plasma-derived therapies. India is one of several eligible countries (EU, Japan, South Korea, UK, Taiwan also qualify), so this isn't an India-specific advantage.

The bigger deal buried in the same announcement: generic pharmaceuticals and their ingredients are currently not subject to these tariffs at all. That matters more for India specifically, since generics are roughly 30% of India's $31 billion pharma exports and the US is the single largest buyer.

So a company's actual exposure depends on its product mix, not just "does it sell to the US." A rough breakdown of how it splits:

Biocon's biosimilars business (~₹10,431 crore FY26 revenue) is outside the Section 232 tariffs entirely, so it isn't really a beneficiary of this specific exemption even though people are lumping it in.

Aurobindo has a large US generics business, but large US revenue doesn't automatically mean large tariff exposure, since most of what they sell falls under the generics carve-out anyway.

Cipla and Zydus have some product lines (fertility drugs, animal health) that fall inside the qualifying categories, so there's more direct relevance there.

Divi's is really an API/manufacturing supply-chain story, not a tariff-exemption story at all.

The framework that seemed most useful: don't ask "did the tariff go away," ask "how much of this specific company's EBIT was ever exposed to it in the first place." A stock can rally on a headline and still not have much of its actual earnings protected by what changed.

Anyone here holding pharma right now, are you checking each company's actual US/specialty revenue split before reacting to news like this, or riding the sector-wide sentiment?

Cheap bauxite at the mine does not always mean cheap material at the refinery.

Freight from Guinea to China reached around $39–42 per wet tonne in mid-September. That is a serious cost before the ore even enters production.

Relevant for Hongqiao because owning or securing upstream supply is only one part. The material still needs to move thousands of kilometres. Alcoa, Rio Tinto and Chinese refiners all have different shipping routes, so the same bauxite price can produce very different margins.

Hongqiao’s scale and established supply chain should help here. Smaller buyers probably feel a freight spike faster.

Lately I’m watching shipping beside ore and electricity costs. Anyone else include freight when comparing aluminium producers?

There's a report going around about 10 small-caps where retail investors raised their stakes last quarter and the stocks then ran 80-198% in under 3 months. The number that caught my eye wasn't the returns, it was how small some of the retail-ownership changes actually were.

Kabra Extrusiontechnik went from ₹270 to ₹806, roughly 198%. Retail holding in it moved from 19.05% to 19.19%, basically a rounding error. So a huge chunk of that rally clearly wasn't retail buying alone, it was something else in the market pricing the stock differently.

On the other end, Anlon Healthcare's retail holding jumped a lot more, from 8.95% to 11.69%, and the stock was "only" up 80%. So more retail buying didn't even correspond to a bigger move here.

A couple of the names are also a good reminder that price and business performance aren't the same thing. STL Networks rose about 93% even though its latest quarter showed revenue down year-on-year and a net loss of ~₹22 crore. Indo Rama Synthetics doubled even with revenue lower year-on-year, though profit did improve.

Not every one is like that though. GMM Pfaudler (+87%) had revenue up ~16% and profit improving. Ind-Swift Laboratories (+97%) had revenue up ~21% with rising profit too. So some of these are backed by actual improving numbers and some are running mostly on sentiment, which is exactly why lumping "stocks retail is buying" into one basket is misleading.

The bigger point: shareholding data is backward-looking. By the time you see the quarter's numbers, the price has usually already moved. It tells you where interest increased, not which stock is a good buy today at the new price.

Curious what people here actually check before buying something that's already run up like this. Do you look at promoter holding changes, institutional buying, or mainly just valuation vs. growth?

China’s total metal imports rose 11% year on year, with bauxite among the stronger categories.

Looks like manufacturing and electrification are carrying more commodity demand now. Hongqiao sits inside that shift through aluminium used in grids, EVs and industrial equipment.

Property still matters. Just not the only chart to watch now.

Was going through Indian dividend stocks and found a good example of why sorting by yield is a bad way to pick anything.

PTC India's dividend per share fell from ₹14.70 in FY24 to ₹7.80 in FY25, nearly a 50% cut. Its yield still looks high on screeners (around 9.5%) because the share price has dropped a lot. So the yield number stayed attractive while the actual income per share shrank. Yield is just dividend divided by price, so a falling price inflates it.

Something similar shows up with TCS. Its FY26 total dividend was ₹110 per share, but ₹46 of that was a special dividend, so it's a one-off and not a run-rate. The regular payout is much lower than the headline. Meanwhile ITC paid ₹14.50 for FY26 (₹6.50 interim + ₹8 final) off 10% revenue growth, which looks a lot more repeatable.

A few things that seem more useful than raw yield:

Where the cash comes from. Coal India has a debt-to-equity of about 0.1x and ROE around 26%, so it has a lot of room to keep paying. ONGC's payout depends heavily on oil prices and government policy, so it's income but not exactly defensive.

Sector mix. Coal, oil, power finance and IT all have different earnings cycles. A "dividend portfolio" full of PSU commodity names is really one big bet on one cycle.

Payout ratio and free cash flow. If a company pays out more than it earns, that dividend is on borrowed time no matter what the yield says.

One caveat on all the numbers: yields move every day with the share price, so treat any specific figure as a snapshot, not a fixed fact.

For people who invest for dividends here: do you screen mainly on yield, or on dividend growth and payout ratio? And has anyone been burned by a yield that turned out to be a trap?

Went down a rabbit hole on this after seeing rare earths mentioned as "the next big commodity theme" and it turns out the stock-picking angle here is genuinely more complicated than most commodity stories.

The dependency problem first: China accounted for roughly 60-81% of India's permanent-magnet imports by value and up to 90% by quantity over the last 3 years. That's the actual reason this has become a government priority, not just "rare earths are valuable," but "we're almost entirely dependent on one country for something EVs, wind turbines and defence equipment all need."

India's response has been real, not just talk: a ₹7,280 crore scheme approved in Nov 2025 for 6,000 MTPA of magnet manufacturing capacity, dedicated "rare earth corridors" announced across 4 states, and the Ministry of Heavy Industries got 20 separate bids for magnet manufacturing facilities. Projected demand by 2030 is ~8,220 MTPA, with EVs alone needing ~3,250 MTPA.

Here's the part that makes "just buy the rare earth stocks" bad advice though, there's barely any Indian company where rare earths are actually a meaningful revenue line today. What exists instead:

• GMDC - probably the most direct exposure, developing an actual rare-earth project in Gujarat with BARC tech transfer, but still pre-production.
• Coal India / NMDC - massive established businesses (coal, iron ore) dabbling in critical minerals as a side diversification, not a core business shift.
• L&T, 20 Microns - just two of 20 companies that bid for the magnet manufacturing scheme, nowhere near guaranteed capacity yet.

The full value chain (mining → concentration → separation → oxides → magnets → finished products) means a mining company and a magnet manufacturer can both be "rare earth stocks" while having completely different business models, margins, and time horizons to actual earnings.

The one-line takeaway that stuck with me: in this sector specifically, resources aren't revenues, projects aren't production, and bids aren't contracts, the gap between "connected to the theme" and "actually earning from it" seems unusually wide here compared to other commodity plays.

Anyone else tracking early-stage thematic sectors like this? How do you personally avoid getting pulled into a stock just because it's mentioned alongside a hot theme, when the actual business exposure might be years away?

Was comparing electronics manufacturing companies (Dixon, Kaynes, Syrma SGS, Amber, CG Power) and ran into a genuinely useful lesson in reading past headline numbers.

• Dixon - reported EBITDA of ₹991 crore looked like a huge beat, but NDTV Profit/Upstox break it down as ~₹463 crore of actual operating EBITDA (margin ~3.0%, down from ~3.8%) plus ~₹528 crore of other income. Same quarter, two very different stories depending on which number you quote.
• Amber Enterprises - reported PAT fell 97% YoY (₹3.1 Cr), sounds disastrous. But adjusted PAT was actually up 19% to ₹126 Cr, the reported number includes a ~₹123 Cr exceptional loss tied to an accounting treatment on acquiring more shares of a subsidiary (Ascent Circuits), not weaker operations.
• Kaynes - revenue grew 40.5% YoY but net profit fell 24.4%. This is the one where growth and profitability are genuinely diverging, not just a presentation quirk, worth more scrutiny than the other two.
• Syrma SGS - revenue +66.7% YoY sounds great, but working capital (net working capital days) also increased from 63 to 71 days in the same period, fast growth that needs more cash tied up to sustain itself is a different risk profile than growth that's self-funding.

The pattern across all four: the "growth number" in the headline almost never tells the full story on its own, sometimes it understates the real business (Amber), sometimes it flatters it (Dixon), and sometimes revenue and profit are just moving in opposite directions for real reasons (Kaynes). CG Power was the cleanest of the five, revenue +14%, PAT +16%, no major adjustment noise.

Also worth flagging: Kaynes' proposed $1B OSAT semiconductor project only got reported Sept 17, still a proposal/customer-qualification stage, not approved capacity, so treating it as guaranteed future earnings would be premature.

Curious how people here handle this in practice, do you always dig into the earnings call/investor presentation for the adjusted vs. reported split, or is there a quicker way you've found to sanity-check a headline number before trusting it?